| SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, Libor HAVEL, Milada ZEMANOVÁ, Dimka SIXTOVÁ, František SALAJKA, Michal HRNČIARIK a Markéta ČERNOVSKÁ. Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1136222,
author = {Skřičková, Jana and Bortlíček, Zbyněk and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Koubková, Leona and Tomíšková, Marcela and Šatánková, Monika and Povolná, Zdenka and Čoupková, Helena and Havel, Libor and Zemanová, Milada and Sixtová, Dimka and Salajka, František and Hrnčiarik, Michal and Černovská, Markéta},
booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
keywords = {NSCLC patients; EGFR mutations},
language = {eng},
title = {Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic},
year = {2013}
}
TY - CONF
ID - 1136222
AU - Skřičková, Jana - Bortlíček, Zbyněk - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Koubková, Leona - Tomíšková, Marcela - Šatánková, Monika - Povolná, Zdenka - Čoupková, Helena - Havel, Libor - Zemanová, Milada - Sixtová, Dimka - Salajka, František - Hrnčiarik, Michal - Černovská, Markéta
PY - 2013
TI - Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic
KW - NSCLC patients
KW - EGFR mutations
N2 - In a group of 74 patients with advanced NSCLC and with activated mutations v/ho were treated with gefitinib in first line, the therapy was well tolerated, median progression-free survival from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and median overall survival (OS) was not reached.
ER -
SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, Libor HAVEL, Milada ZEMANOVÁ, Dimka SIXTOVÁ, František SALAJKA, Michal HRNČIARIK a Markéta ČERNOVSKÁ. Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864.
|
